查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1625427

CAR-T細胞療法市場，規模，佔有率，趨勢，產業分析報告:各適應症，標的抗原，各地區 - 市場預測，2025年～2034年

CAR-T Cell Therapy Market Size, Share, Trends, Industry Analysis Report: By Indication, Target Antigen, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，預計到 2034 年，全球 CAR-T 細胞治療市場規模將達到 1888.4 億美元。該報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

嵌合抗原受體 T 細胞 (CAR-T) 療法代表了癌症治療的進步，並徹底改變了免疫腫瘤學。這種治療是個人化的，透過改造患者的 T 細胞來表達針對特定癌症抗原的合成受體，對特定癌症（特別是血液系統惡性腫瘤）非常有效，從而提供了廣泛的治療選擇。在生物技術的快速進步、CAR-T療法批准率的提高以及對創新癌症治療的需求不斷增長的推動下，全球CAR-T細胞療法市場在過去十年中經歷了快速增長。

全球癌症發生率不斷上升，以及對精準醫療的日益青睞，推動了對 CAR-T 細胞療法等先進療法的需求。此外，支持性監管框架和加速審批途徑正在加速 CAR-T 療法的上市。政府和私人研究投資正在進一步推動CAR-T細胞治療市場的擴張。

下一代 CAR-T 療法（包括多標靶 CAR-T 細胞和裝甲 CAR-T 細胞）的發展正在推動 CAR-T 細胞療法市場的成長。多標靶 CAR-T 細胞旨在識別多種抗原，解決腫瘤異質性和抗原逃脫等限制傳統 CAR-T 治療有效性的問題。武裝CAR-T細胞旨在透過分泌細胞激素和其他分子來克服免疫抑制的腫瘤微環境，從而增強抗腫瘤活性。

CAR-T 療法的應用正在擴展到腫瘤學之外。研究人員正在探索其治療狼瘡和多發性硬化症等自體免疫疾病以及愛滋病毒等傳染病的潛力。這些新應用預計將顯著擴大市場範圍和影響力。

CAR-T 細胞治療市場報告亮點

有跡象表明，濾泡性淋巴瘤 (FL) 領域預計將以最快的速度增長，在預測期內複合年增長率為 43.2%。

基於標靶抗原，CD19/CD22抗原片段在瀰漫性大B細胞淋巴瘤（DLBCL）和急性淋巴性白血病（ALL）等B細胞惡性腫瘤的治療中具有明確的作用並受到重視。達到62585億美元，佔最大市場佔有率。

在全球市場中，2024年北美CAR-T細胞治療市場佔47.16%的市佔率。這是由於先進的醫療基礎設施、高研發投資和血液惡性腫瘤的高盛行率。

由於復發性或難治性血癌盛行率上升以及人們越來越關注擴大先進治療的可及性，歐洲CAR-T 細胞治療市場將在預測期內增長，預計複合年增長率為33.2 %。

作為全球主要市場企業的一個例子，Bluebird Bio，Celgene Corporation，Gilead Sciences，Cellectis，Servier Laboratories，Pfizer Inc.，Merck，Amgen，Intellia Therapeutics，Novartis，Caribou Biosciences，Celyad，Bellicum Pharmaceuticals，Noile-Immune Biotech，南京市 Legend Biotechnology Co.等能舉出(舉行)。

目錄

第1章 簡介

  • 報告的說明
    • 研究的目的
    • 市場範圍
  • 前提條件
  • 利害關係者
  • 簡稱一覽

第2章 摘要整理

  • 市場概況

第3章 調查手法

  • 概要
    • 資料探勘
  • 資料來源
    • 一次資訊
    • 二次資訊

第4章 CAR-T細胞療法市場洞察

  • CAR-T細胞療法市場動態
    • 促進因素和機會
      • 白血病領域前景廣闊，DLBCL 和多發性骨髓瘤新藥上市
      • 應用於實體腫瘤的可能性
    • 阻礙因素與課題
      • 患者復發
      • 製造與物流課題
      • 經濟模型/報銷/擴展
  • PEST分析
  • CAR-T細胞療法開發時間表
  • CAR-T細胞製造的前景
  • CAR-T細胞的副作用
  • 針對實體瘤的抗原
  • CAR-T臨床試驗狀況
  • 商業格局（併購、夥伴關係和合作）
  • CAR-T療法的新創新
    • "現成的" CAR-T 或類似的 CAR-T
    • 雙 CAR-T 開發
    • 非病毒轉錄技術的發展
    • TIL 和 TCR 療法的出現
      • TCR（T 細胞受體）
      • TIL（腫瘤浸潤淋巴球）
  • 電暈影響分析
  • 客製化 - CAR-T 細胞市場

第5章 CAR-T細胞療法市場評估:各適應症

  • 簡介
  • DLBCL
  • ALL
  • CLL
  • MM
  • FL
  • 肥胖細胞症
  • 骨髓纖維化
  • MLLL
  • 胸腺癌症
  • 神經膠母細胞瘤
  • AML
  • 其他的適應症

第6章 全球CAR-T細胞療法市場:標的抗原

  • 簡介
  • CD19/CD22
  • BCMA
  • 其他

第7章 CAR-T細胞療法市場評估:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 奧地利
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
  • 南美
    • 巴西
    • 墨西哥
  • 中東·非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第8章 競爭情形

  • 產品的銷售和收購是被企業最僱用的策略
  • 產品銷售
  • 聯盟/合作/協定/公開

第9章 企業簡介

  • Bluebird Bio
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Celgene Corporation
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Gilead Sciences, Inc.
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Cellectis
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Servier Laboratories
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Pfizer Inc.
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Merck KGaA
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Amgen Inc.
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Intellia Therapeutics
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Novartis International AG
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Caribou Biosciences, Inc
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Celyad
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Bellicum Pharmaceuticals, Inc.
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Noile-Immune Biotech
    • 公司概要
    • 產品基準
    • 最近的開發
  • Nanjing Legend Biotechnology Co., Ltd.
    • 公司概要
    • 產品基準
    • 最近的開發
  • Johnson & Johnson
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
  • Sangamo Therapeutics, Inc.
    • 公司概要
    • 財務實際成果
    • 產品基準
    • 最近的開發
Product Code: PM1389

The global CAR-T cell therapy market size is expected to reach USD 188.84 billion by 2034, according to a new study by Polaris Market Research. The report "CAR-T Cell Therapy Market Size, Share, Trends, Industry Analysis Report: By Indication, Target Antigen [CD19/CD22, BCMA (B-Cell Maturation Antigen), and Others], and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Chimeric Antigen Receptor T-cell (CAR-T) therapy represents an advancement in cancer treatment, transforming immuno-oncology. The therapy offers personalized and highly effective treatment options for certain cancers, particularly hematological malignancies, by engineering a patient's T-cells to express synthetic receptors that target specific cancer antigens. The global CAR-T cell therapy market has witnessed exponential growth over the last decade, driven by rapid advancements in biotechnology, increasing approval rates of CAR-T therapies, and rising demand for innovative cancer treatments.

The increasing prevalence of cancer globally, coupled with a growing preference for precision medicine, has fueled demand for advanced treatment modalities such as CAR-T cell therapy. Moreover, supportive regulatory frameworks and rapid approval pathways have accelerated the availability of CAR-T therapies. Government and private investments in research further propel the CAR-T cell therapy market expansion.

The development of next-generation CAR-T therapies, including multi-target CAR-T cells and armored CAR-T cells, is driving the CAR-T cell therapy market growth. Multi-target CAR-T cells are engineered to recognize multiple antigens, addressing issues such as tumor heterogeneity and antigen escape, which limit the efficacy of traditional CAR-T treatments. Armored CAR-T cells are designed to overcome the immunosuppressive tumor microenvironment by secreting cytokines or other molecules to enhance anti-tumor activity.

The application of CAR-T therapy is expanding beyond oncology. Researchers are exploring its potential in treating autoimmune diseases such as lupus and multiple sclerosis and infectious diseases, including HIV. These novel applications are estimated to significantly broaden the market scope and impact.

CAR-T Cell Therapy Market Report Highlights

In terms of indication, the follicular lymphoma (FL) segment is expected to grow at the fastest pace, with a CAGR of 43.2% during the forecast period due to the rising incidence of refractory and high-risk cancer cases.

Based on target antigen, the CD19/CD22 antigen segment, valued at USD 6,258.5 billion in 2024, held the largest market share owing to its established role in treating B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL).

In the global market, the North America CAR-T cell therapy market held a 47.16% market share in 2024 due to the presence of advanced healthcare infrastructure, significant research and development investments, and a high prevalence of hematologic malignancies.

The Europe CAR-T cell therapy market is expected to witness a CAGR of 33.2% during the forecast period due to increased focus on expanding access to advanced therapies, coupled with the rising prevalence of relapsed or refractory hematologic cancers.

A few of the global key market players are Bluebird Bio; Celgene Corporation; Gilead Sciences; Cellectis; Servier Laboratories; Pfizer Inc.; Merck; Amgen; Intellia Therapeutics; Novartis; Caribou Biosciences; Celyad; Bellicum Pharmaceuticals, Inc.; Noile-Immune Biotech; Nanjing Legend Biotechnology Co., Ltd.; Johnson & Johnson; and Sangamo Therapeutics, Inc.

Polaris Market Research has segmented the CAR-T cell therapy market report on the basis of indication, antigen, and region:

By Indication Outlook (Revenue, USD Billion, 2020-2034)

  • DLBCL (Diffuse large B-cell lymphoma)
  • ALL (Acute Lymphoblastic Leukemia)
  • CLL (Chronic Lymphocytic Leukemia)
  • MM (Multiple Myeloma)
  • FL (Follicular Lymphoma)
  • Mastozytosis
  • Myeloid Fibrosis
  • MLL (Mixed Lineage Leukemia)
  • Thymic Cancer
  • Glioblastoma
  • AML (Acute Myeloid Leukemia)
  • Other

By Target Antigen Outlook (Revenue, USD Billion, 2020-2034)

  • CD19/CD22
  • BCMA (B-Cell Maturation Antigen)
  • Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

Chapter 1. Introduction

  • 1.1 Report Description
    • 1.1.1 Objectives of the Study
    • 1.1.2 Market Scope
  • 1.2 Assumptions
  • 1.3 Stakeholders
  • 1.4 List of Abbreviations

Chapter 2. Executive Summary

  • 2.1 Market Highlights

Chapter 3. Research Methodology

  • 3.1 Overview
    • 3.1.1 Data Mining
  • 3.2 Data Sources
    • 3.2.1 Primary Sources
    • 3.2.2 Secondary Sources

Chapter 4. CAR-T Cell Therapy Market Insights

  • 4.1 CAR-T Cell Therapy Market Dynamics
    • 4.1.1 Drivers and Opportunities
      • 4.1.1.1 Promising growth in leukemia segment for DLBCL and Multiple Myeloma coupled with launches
      • 4.1.1.2 Potential applications in solid tumor
    • 4.1.2 Restraints and Challenges
      • 4.1.2.1 Patient Relapse
      • 4.1.2.2 Manufacturing and logistics challenges
      • 4.1.2.3 Economic model/reimbursement/scaling
  • 4.2 Porter's Five Forces Analysis
    • 4.2.1 Bargaining Power of Suppliers (High)
    • 4.2.2 Threats of New Entrants: (High)
    • 4.2.3 Bargaining Power of Buyers (Low)
    • 4.2.4 Threat of Substitute (Low)
    • 4.2.5 Rivalry among existing firms (High)
  • 4.3 PEST Analysis
  • 4.4 Timeline of CAR-T Cell Therapy Development
  • 4.5 CAR-T Cell Manufacturing Outlook
  • 4.6 Side-effects of CAR-T Cell
  • 4.7 Antigens targeting solid tumors
  • 4.8 Clinical trials Landscape for CAR-T
  • 4.9 Commercial Landscape (Mergers & Acquisitions, Partnerships & Collaborations)
  • 4.10 New Innovations in CAR-T therapies
    • 4.10.1 "Off-the-shelf" CAR-T or allogenic CAR-T
    • 4.10.2 Development of Dual CAR-T
    • 4.10.3 Development of Non-viral transcription technologies
    • 4.10.4 The advent of TIL as well as TC R therapies
      • 4.10.4.1 TCR (T-cell receptor)
      • 4.10.4.2 TIL (Tumor-Infiltrating Lymphocytes)
  • 4.11 CAR-T Cell Therapy Market - Covid Impact Analysis
  • 4.12 Customization - CAR-T Cell Market

Chapter 5. CAR-T Cell Therapy Market Assessment by Indication

  • 5.1 Introduction
  • 5.2 DLBCL
  • 5.3 ALL
  • 5.4 CLL
  • 5.5 MM
  • 5.6 FL
  • 5.7 Mastozytosis
  • 5.8 Myeloid Fibrosis
  • 5.9 MLL
  • 5.10 Thymic Cancer
  • 5.11 Glioblastoma
  • 5.12 AML
  • 5.13 Other Indications

Chapter 6. Global CAR-T Cell Therapy Market, by Target Antigen

  • 6.1 Introduction
  • 6.2 CD19/CD22
  • 6.3 BCMA
  • 6.4 Others

Chapter 7. CAR-T Cell Therapy Market Assessment by Geography

  • 7.1 Introduction
  • 7.2 CAR-T Cell Therapy Market - North America
    • 7.2.1 CAR-T Cell Therapy Market - U.S.
    • 7.2.2 CAR-T Cell Therapy Market - Canada
  • 7.3 CAR-T Cell Therapy Market - Europe
    • 7.3.1 CAR-T Cell Therapy Market - Germany
    • 7.3.2 CAR-T Cell Therapy Market - UK
    • 7.3.3 CAR-T Cell Therapy Market - France
    • 7.3.4 CAR-T Cell Therapy Market - Italy
    • 7.3.5 CAR-T Cell Therapy Market - Spain
    • 7.3.6 CAR-T Cell Therapy Market - Netherlands
    • 7.3.7 CAR-T Cell Therapy Market - Austria
  • 7.4 CAR-T Cell Therapy Market - Asia Pacific
    • 7.4.1 CAR-T Cell Therapy Market - China
    • 7.4.2 CAR-T Cell Therapy Market - India
    • 7.4.3 CAR-T Cell Therapy Market - Japan
    • 7.4.4 CAR-T Cell Therapy Market - South Korea
    • 7.4.5 CAR-T Cell Therapy Market - Australia
  • 7.5 CAR-T Cell Therapy Market - Latin America
    • 7.5.1 CAR-T Cell Therapy Market - Brazil
    • 7.5.2 CAR-T Cell Therapy Market - Mexico
  • 7.6 CAR-T Cell Therapy Market - Middle East & Africa
    • 7.6.1 CAR-T Cell Therapy Market - Saudi Arabia
    • 7.6.2 CAR-T Cell Therapy Market - UAE

Chapter 8. Competitive Landscape

  • 8.1 Product Launch and Acquisition Are the Best Adopted Strategy by the Companies
  • 8.2 Product Launch
  • 8.3 Partnerships/Collaborations/Agreements/Exhibitions

Chapter 9. Company Profiles

  • 9.1 Bluebird Bio
    • 9.1.1 Company Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Benchmarking
    • 9.1.4 Recent Development
  • 9.2 Celgene Corporation
    • 9.2.1 Company Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Benchmarking
    • 9.2.4 Recent Development
  • 9.3 Gilead Sciences, Inc.
    • 9.3.1 Company Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Benchmarking
    • 9.3.4 Recent Development
  • 9.4 Cellectis
    • 9.4.1 Company Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Benchmarking
    • 9.4.4 Recent Development
  • 9.5 Servier Laboratories
    • 9.5.1 Company Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Benchmarking
    • 9.5.4 Recent Development
  • 9.6 Pfizer Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Benchmarking
    • 9.6.4 Recent Development
  • 9.7 Merck KGaA
    • 9.7.1 Company Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Benchmarking
    • 9.7.4 Recent Development
  • 9.8 Amgen Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Benchmarking
    • 9.8.4 Recent Development
  • 9.9 Intellia Therapeutics
    • 9.9.1 Company Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Benchmarking
    • 9.9.4 Recent Development
  • 9.10 Novartis International AG
    • 9.10.1 Company Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Benchmarking
    • 9.10.4 Recent Development
  • 9.11 Caribou Biosciences, Inc
    • 9.11.1 Company Overview
    • 9.11.2 Financial Performance
    • 9.11.3 Product Benchmarking
    • 9.11.4 Recent Development
  • 9.12 Celyad
    • 9.12.1 Company Overview
    • 9.12.2 Financial Performance
    • 9.12.3 Product Benchmarking
    • 9.12.4 Recent Development
  • 9.13 Bellicum Pharmaceuticals, Inc.
    • 9.13.1 Company Overview
    • 9.13.2 Financial Performance
    • 9.13.3 Product Benchmarking
    • 9.13.4 Recent Development
  • 9.14 Noile-Immune Biotech
    • 9.14.1 Company Overview
    • 9.14.2 Product Benchmarking
    • 9.14.3 Recent Development
  • 9.15 Nanjing Legend Biotechnology Co., Ltd.
    • 9.15.1 Company Overview
    • 9.15.2 Product Benchmarking
    • 9.15.3 Recent Development
  • 9.16 Johnson & Johnson
    • 9.16.1 Company Overview
    • 9.16.2 Financial Performance
    • 9.16.3 Product Benchmarking
    • 9.16.4 Recent Development
  • 9.17 Sangamo Therapeutics, Inc.
    • 9.17.1 Company Overview
    • 9.17.2 Financial Performance
    • 9.17.3 Product Benchmarking
    • 9.17.4 Recent Development

List of Tables

Table 1 Selected significant catalysts in CAR-T

Table 2 Various antigen targets are investigated for solid tumors

Table 3 Top Developers in CAR T cell clinical trials (September 2019)

Table 4 Catalyst for Small Players

Table 5 Selected deals and partnerships

Table 6 Cost of production (Lentivirus), 2022, (USD Billion)

Table 7 Cost of production (Plasmid), 2022, (USD Billion)

Table 8 Reimbursement amounts for CAR-T therapies per region, 2022, (USD Billion)

Table 9 Global CAR-T Cell Therapy Market, by Indication, 2020-2034, (USD Billion)

Table 10 Global CAR-T Cell Therapy Market, by DLBCL, 2020-2034, (USD Billion)

Table 11 Global CAR-T Cell Therapy Market, by ALL, 2020-2034, (USD Billion)

Table 12 Global CAR-T Cell Therapy Market, by CLL, 2020-2034, (USD Billion)

Table 13 Global CAR-T Cell Therapy Market, by MM, 2020-2034, (USD Billion)

Table 14 Global CAR-T Cell Therapy Market, by FL, 2020-2034, (USD Billion)

Table 15 Global CAR-T Cell Therapy Market, by Mastozytosis, 2020-2034, (USD Billion)

Table 16 Global CAR-T Cell Therapy Market, by Myeloid Fibrosis, 2020-2034, (USD Billion)

Table 17 Global CAR-T Cell Therapy Market, by MLL, 2020-2034, (USD Billion)

Table 18 Global CAR-T Cell Therapy Market, by Thymic Cancer, 2020-2034, (USD Billion)

Table 19 Global CAR-T Cell Therapy Market, by Glioblastoma, 2020-2034, (USD Billion)

Table 20 Global CAR-T Cell Therapy Market, by AML, 2020-2034, (USD Billion)

Table 21 Global CAR-T Cell Therapy Market, by Other Indications, 2020-2034, (USD Billion)

Table 22 Global CAR-T Cell Therapy Market, By Target Antigen, 2015 - 2026 (USD Billion)

  • Table 23 Global CAR-T Cell Therapy Market, by CD19/CD22, by Region, 2020-2034, (USD Billion)
  • Table 24 Global CAR-T Cell Therapy Market, by BCMA, 2020-2034, (USD Billion)
  • Table 25 Global CAR-T Cell Therapy Market, by Others, 2020-2034, (USD Billion)

Table 26 CAR-T Cell Therapy Market Assessment, By Geography, 2020-2034, (USD Billion)

Table 27 North America: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 28 North America: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 29 U.S.: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 30 U.S.: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 31 Canada: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 32 Canada: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 33 Europe: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 34 Europe: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 35 Germany: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 36 Germany: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 37 UK: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 38 UK: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 39 France: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 40 France: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 41 Italy: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 42 Italy: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 43 Spain: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 44 Spain: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 45 Netherlands: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 46 Netherlands: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 47 Austria: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 48 Austria: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 49 Asia Pacific: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 50 Asia Pacific: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 51 China: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 52 China: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 53 India: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 54 India: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 55 Japan: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 56 Japan: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 57 South Korea: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 58 South Korea: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 59 Australia: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 60 Australia: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 61 Latin America: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 62 Latin America: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 63 Brazil: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 64 Brazil: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 65 Mexico: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 66 Mexico: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 67 Middle East & Africa: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 68 Middle East & Africa: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 69 Saudi Arabia: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 70 Saudi Arabia: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 71 UAE: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 72 UAE: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

  • List of Figures
  • Figure 1. Market Highlights
  • Figure 2. Research Methodology: Top Down & Bottom Up Approach
  • Figure 3. Porter's Five Forces
  • Figure 4. CAR-T Timelines
  • Figure 5. CAR-T manufacturing process of Kymriah (Novartis)
  • Figure 6. Market by Indication
  • Figure 7. Market by Target Antigen